We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chasing a cellular fountain of youth.
- Authors
Wilan, Ken Howard; Scott, Christopher Thomas; Herrera, Stephan
- Abstract
The article reports that biotech companies with business models as diverse as the products they are developing are laboring to move cell-based therapies into the clinic. Without a commercial success, however, investors will remain on the sidelines. Although human embryonic stem (ES) cells get all the attention, dozens of companies are quietly chasing cell-based therapeutics derived from a variety of adult stem and progenitor cells for treating everything from heart attacks to cancer. This is not the first time-out for cell-based therapies and regenerative medicine. Because of the problems with investment and the fact that timelines are long and outcomes uncertain for companies developing clinical therapies, some enterprises are taking a different tack.
- Subjects
BUSINESS planning; THERAPEUTICS; EMBRYONIC stem cells; MYOCARDIAL infarction; CANCER; INVESTMENTS; INVESTORS
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 7, p807
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0705-807